«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 07

Page:

1350-1355

Research Field:

Publishing date:

Info

Title:

Progress of compounds for hepatocellular carcinoma associated with non-alcoholic fatty liver disease

Author(s):

WANG Yanxiu¹; HAO Dandan²

1.Gastroenterology Department,the Affiliated Hospital of Chifeng University,Inner Mongolia Chifeng 024005,China;2.Department of Physiology,Medical College,Chifeng University,Inner Mongolia Chifeng 024000,China

Keywords:

hepatocellular carcinoma; non-alcoholic fatty liver disease; NAFLD-driven HCC; treatment

PACS:

R735.7

DOI:

10.3969/j.issn.1672-4992.2024.07.030

Abstract:

Non-alcoholic fatty liver disease (NAFLD) has become a serious global health threat,and is expected to become the leading cause of hepatocellular carcinoma (HCC),resulting in NAFLD-driven HCC in the near future.Until now,the molecular mechanisms underlying NAFLD-driven HCC remain largely unknown.Currently,an increasing number of studies are focusing on the utility of natural products in NAFLD and NAFLD-driven HCC.In this review,we first briefly presented the recent progress of the possible mechanisms underling the pathogenesis and progression of NAFLD-driven HCC.Then we overview the application of natural products to mitigate NAFLD-driven HCC,classifing these compounds that treat NAFLD-driven HCC into five mechanisms through anti-inflammation,anti-oxidative stress,regulating lipid metabolism,regulating gut microbiota,and inhibiting liver fibrosis.This review provided valuable information for future treatment and prevention of NAFLD-driven HCC.

References:

£Û1£ÝSHAH PA,PATIL R,HARRISON SA.NAFLD-related hepatocellular carcinoma:The growing challenge£ÛJ£Ý.Hepatology,2023,77(1):323-338.
£Û2£ÝZHOU F,ZHOU J,WANG W,et al.Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and meta-analysis£ÛJ£Ý.Hepatology,2019,70(4):1119-1133.
£Û3£ÝÑÕÊ¿ÑÒ,·¶½¨¸ß.·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡Ïà¹Ø¸Îϸ°û°©µÄÕï¶ÏºÍÖÎÁÆ£ÛJ£Ý.ÁÙ´²¸Îµ¨²¡ÔÓÖ¾,2021,37(08):1748-1752. YAN SY,FAN JG.Diagnosis and treatment of hepatocellular carcinoma associated with nonalcoholic fatty liver disease£ÛJ£Ý.J Clin Hepatol,2021,37(8):1748-1752.
£Û4£ÝYIP TC,LEE HW,CHAN WK,et al.Asian perspective on NAFLD-associated HCC£ÛJ£Ý.Journal of Hepatology,2022,76(3):726-734.
£Û5£ÝDE MINICIS S,AGOSTINELLI L,RYCHLICKI C,et al.HCC development is associated to peripheral insulin resistance in a mouse model of NASH£ÛJ£Ý.PLoS One,2014,9(5):e97136.
£Û6£ÝJANKU F,KASEB AO,TSIMBERIDOU AM,et al.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing£ÛJ£Ý.Oncotarget,2014,5(10):3012-3022.
£Û7£ÝYANG S,LIU G.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma£ÛJ£Ý.Oncology Letters,2017,13(3):1041-1047.
£Û8£ÝDE CONTI A,ORTEGA JF,TRYNDYAK V,et al.MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis£ÛJ£Ý.Oncotarget,2017,8(51):88517-88528.
£Û9£ÝGAUTHERON J,VUCUR M,REISINGER F,et al.A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis£ÛJ£Ý.EMBO Molecular Medicine,2014,6(8):1062-1074.
£Û10£ÝHIRSOVA P,IBRABIM SH,GORES GJ,et al.Lipotoxic lethal and sublethal stress signaling in hepatocytes:relevance to NASH pathogenesis£ÛJ£Ý.Journal of Lipid Research,2016,57(10):1758-1770.
£Û11£ÝBOZAYKUT P,SAHIN A,KARADEMIR B,et al.Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic steatohepatitis£ÛJ£Ý.Mechanisms of Ageing and Development,2016,157:17-29.
£Û12£ÝFU S,YANG L,LI P,et al.Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity£ÛJ£Ý.Nature,2011,473(7348):528-531.
£Û13£ÝANSTEE QM,REEVES HL,KOTSILITI E,et al.From NASH to HCC:Current concepts and future challenges.Nature reviews£ÛJ£Ý.Gastroenterology & Hepatology,2019,16(7):411-428.
£Û14£ÝPONZIANI FR,BHOORI S,CASTELLI C,et al.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease£ÛJ£Ý.Hepatology,2019,69(1):107-120.
£Û15£ÝCHU H,WILLIAMS B,SCHNABL B.Gut microbiota,fatty liver disease,and hepatocellular carcinoma£ÛJ£Ý.Liver Research,2018,2(1):43-51.
£Û16£ÝRAHMAN K,DESAI C,IYER SS,et al.Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat,fructose,and cholesterol£ÛJ£Ý.Gastroenterology,2016,151(4):733-746.
£Û17£ÝYU LX,SCHWABE RF.The gut microbiome and liver cancer:mechanisms and clinical translation.Nature reviews£ÛJ£Ý.Gastroenterology & Hepatology,2017,14(9):527-539.
£Û18£ÝPARK EJ,LEE JH,YU GY,et al.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression£ÛJ£Ý.Cell,2010,140(2):197-208.
£Û19£ÝWOLF MJ,ADILI A,PIOTROWITZ K,et al.Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes£ÛJ£Ý.Cancer Cell,2014,26(4):549-564.
£Û20£ÝKANG TW,YEVSA T,WOLLER N,et al.Senescence surveillance of pre-malignant hepatocytes limits liver cancer development£ÛJ£Ý.Nature,2011,479(7374):547-551.
£Û21£ÝRAKHRA K,BACHIREDDY P,ZABUAWALA T,et al.CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation£ÛJ£Ý.Cancer Cell,2010,18(5):485-498.
£Û22£ÝMA C,KESARWALA AH,EGGERT T,et al.NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis£ÛJ£Ý.Nature,2016,531(7593):253-257.
£Û23£ÝSHALAPOUR S,LIN XJ,BASTIAN IN,et al.Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity£ÛJ£Ý.Nature,2017,551(7680):340-345.
£Û24£ÝMALEHMIR M,PFISTER D,GALLAGE S,et al.Platelet GPIb¦Á is a mediator and potential interventional target for NASH and subsequent liver cancer£ÛJ£Ý.Nature Medicine,2019,25(4):641-655.
£Û25£ÝTAJIMA K,NAKAMURA A,SHIRAKAWA J,et al.Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.American journal of physiology£ÛJ£Ý.Endocrinology and Metabolism,2013,305(8):E987-998.
£Û26£ÝIP BC,HU KQ,LIU C,et al.Lycopene metabolite,apo-10'-lycopenoic acid,inhibits diethylnitrosamine-initiated,high fat diet-promoted hepatic inflammation and tumorigenesis in mice£ÛJ£Ý.Cancer Prevention Research,2013,6(12):1304-1316.
£Û27£ÝKOJIMA M,TAKAHASHI H,KUWASHIRO T,et al.Glucagon-like peptide-1 receptor agonist prevented the progression of hepato cellular carcinoma in a mouse model of nonalcoholic steatohepatitis£ÛJ£Ý.International Rournal of Molecular Sciences,2020,21(16)£º5722.
£Û28£ÝDE OLIVEIRA S,HOUSERIGHT RA,GRAVES AL,et al.Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish£ÛJ£Ý.Journal of Hepatology,2019,70(4):710-721.
£Û29£ÝQIN CJ,ZHAO LH,ZHOU X,et al.Inhibition of dipeptidyl peptidase ¢ô prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2£ÛJ£Ý.Cancer Letters,2018,420:26-37.
£Û30£ÝYOKOHAMA K,FUKUNISHI S,LI M,et al.Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice£ÛJ£Ý.International Rournal of Molecular Medicine,2016,38(5):1499-1506.
£Û31£ÝIP BC,LIU C,AUSMAN LM,et al.Lycopene attenuated hepatic tumorigenesis via differential mechanisms depending on carotenoid cleavage enzyme in mice£ÛJ£Ý.Cancer Prevention Research,2014,7(12):1219-1227.
£Û32£ÝLUO Y,TIAN G,ZHUANG Z,et al.Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice£ÛJ£Ý.American Journal of Translational Research,2019,11(5):2668-2682.
£Û33£ÝAFRIN R,ARUMUGAM S,RAHMAN A,et al.Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-¦ÊB translocation£ÛJ£Ý.International Immunopharmacology,2017,44:174-182.
£Û34£ÝWANG Y,AUSMAN LM,GREENBERG AS,et al.Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats£ÛJ£Ý.International Journal of Cancer,2010,126(8):1788-1796.
£Û35£ÝZHANG Y,LI X,LI X.Curcumae ameliorates diethylnitrosamine-induced hepatocellular carcinoma via alteration of oxidative stress,inflammation and gut microbiota£ÛJ£Ý.Journal of Inflammation Research,2021,14:5551-5566.
£Û36£ÝXIA H,LIU C,LI CC,et al.Dietary tomato powder inhibits high-fat diet-promoted hepatocellular carcinoma with alteration of gut microbiota in mice lacking carotenoid cleavage enzymes£ÛJ£Ý.Cancer Prevention Research,2018,11(12):797-810.
£Û37£ÝKUO J,SERRANO SS,GR¦ZNBERG A,et al.Cyclophilin inhibitor NV556 reduces fibrosis and hepatocellular carcinoma development in mice with non-alcoholic steatohepatitis£ÛJ£Ý.Frontiers in Pharmacology,2019,10:1129.
£Û38£ÝLI S,GHOSHAL S,SOJOODI M,et al.Pioglitazone reduces hepatocellular carcinoma development in two rodent models of cirrhosis£ÛJ£Ý.Journal of Gastrointestinal Surgery,2019,23(1):101-111.
£Û39£ÝMIURA K,OHNISHI H,MORIMOTO N,et al.Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet£ÛJ£Ý.Cancer Science,2019,110(2):771-783.
£Û40£ÝLIEBIG M,DANNENBERGER D,VOLLMAR B,et al.n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model£ÛJ£Ý.Therapeutic Advances in Chronic Disease,2019,10:2040622319872118.
£Û41£ÝWAKAME K,SATO K,KASAI M,et al.Oral administration of mulberry (Morus alba L.) leaf powder prevents the development of hepatocellular carcinoma in stelic animal model (STAM) mice£ÛJ£Ý.Anticancer Research,2022,42(8):4055-4062.
£Û42£ÝOKUDA K,UMEMURA A,UMEMURA S,et al.Honokiol prevents non-alcoholic steatohepatitis-induced liver cancer via EGFR degradation through the glucocorticoid receptor-MIG6 axis£ÛJ£Ý.Cancers,2021,13(7):1515.
£Û43£ÝINOUE-YAMAUCHI A,ITAGAKI H,ODA H.Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis£ÛJ£Ý.Carcinogenesis,2018,39(1):28-35.
£Û44£ÝLIM JY,LIU C,HU KQ,et al.Ablation of carotenoid cleavage enzymes (BCO1 and BCO2) induced hepatic steatosis by altering the farnesoid X receptor/miR-34a/sirtuin 1 pathway£ÛJ£Ý.Archives of Biochemistry and Biophysics,2018,654:1-9.
£Û45£ÝKHAZAALEH S,SARMINI MT,ALOMARI M,et al.Statin use reduces the risk of hepatocellular carcinoma:An updated meta-analysis and systematic review£ÛJ£Ý.Cureus,2022,14(7):e27032.

Memo

Memo:

ÄÚÃɹÅ×ÔÈ»¿Æѧ»ù½ð(±àºÅ£º2022MS08032)

Common functions

Last Update: 2024-02-29